Sutro Biopharma (STRO) Capital Expenditures (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Capital Expenditures data on file, last reported at $184000.0 in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures fell 92.4% year-over-year to $184000.0; the trailing twelve-month figure through Dec 2025 stood at $1.7 million (down 45.29% YoY), and the FY2025 full-year result was $1.7 million, down 45.29% from the prior year.
• Capital Expenditures declined to $184000.0 in Q4 2025, from $1.5 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $13.2 million in Q4 2021 to a low of -$2.2 million in Q3 2023.
• A 5-year average of $1.0 million and a median of $661500.0 in 2021 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures plunged 350.7% in 2022 and jumped 2243.36% in 2024, its largest moves.
• Tracing STRO's Capital Expenditures over 5 years: stood at $13.2 million in 2021, then plunged by 111.36% to -$1.5 million in 2022, then surged by 92.44% to -$113000.0 in 2023, then jumped by 2243.36% to $2.4 million in 2024, then tumbled by 92.4% to $184000.0 in 2025.
• Business Quant data shows STRO's Capital Expenditures at $184000.0 in Q4 2025, $1.5 million in Q3 2025, and -$4000.0 in Q2 2025.